HK1163119A1 - Anti cxcr4 antibodies and their use for the treatment of cancer cxcr4 - Google Patents

Anti cxcr4 antibodies and their use for the treatment of cancer cxcr4

Info

Publication number: HK1163119A1
Authority: HK; Hong Kong
Prior art keywords: cxcr4; treatment; cancer; antibodies; cxcr4 antibodies
Prior art date: 2008-10-01

Application number

HK12103380.8A

Other languages

English (en)

Chinese (zh)

Inventor

．克林格-阿穆

．格勒尼耶-科薩內爾

Original Assignee

皮埃爾法布雷醫藥公司

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-01

Filing date

2012-04-05

Publication date

2012-09-07

2012-04-05 Application filed by 皮埃爾法布雷醫藥公司 filed Critical 皮埃爾法布雷醫藥公司

2012-09-07 Publication of HK1163119A1 publication Critical patent/HK1163119A1/xx

Links

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

HK12103380.8A 2008-10-01 2012-04-05 Anti cxcr4 antibodies and their use for the treatment of cancer cxcr4 HK1163119A1 (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US13677208P	2008-10-01	2008-10-01
EP08305631A EP2172485A1 (en)	2008-10-01	2008-10-01	Novel anti CXCR4 antibodies and their use for the treatment of cancer
US17374309P	2009-04-29	2009-04-29
PCT/EP2009/062787 WO2010037831A1 (en)	2008-10-01	2009-10-01	Anti cxcr4 antibodies and their use for the treatment of cancer

Publications (1)

Publication Number	Publication Date
HK1163119A1 true HK1163119A1 (en)	2012-09-07

Family

ID=40361774

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK12103380.8A HK1163119A1 (en)	2008-10-01	2012-04-05	Anti cxcr4 antibodies and their use for the treatment of cancer cxcr4

Country Status (29)

Country	Link
US (4)	US8557964B2 (xx)
EP (2)	EP2172485A1 (xx)
JP (1)	JP5723279B2 (xx)
KR (1)	KR101671039B1 (xx)
CN (1)	CN102209730B (xx)
AR (1)	AR073748A1 (xx)
AU (1)	AU2009299787B2 (xx)
BR (1)	BRPI0920531A2 (xx)
CA (1)	CA2738782C (xx)
CL (1)	CL2011000730A1 (xx)
CY (1)	CY1115572T1 (xx)
DK (1)	DK2342233T3 (xx)
ES (1)	ES2503732T3 (xx)
GE (1)	GEP20146084B (xx)
HK (1)	HK1163119A1 (xx)
HR (1)	HRP20140899T1 (xx)
IL (1)	IL212066A (xx)
MA (1)	MA32928B1 (xx)
MX (1)	MX2011003509A (xx)
NZ (1)	NZ592363A (xx)
PL (1)	PL2342233T3 (xx)
PT (1)	PT2342233E (xx)
RS (1)	RS53578B1 (xx)
RU (1)	RU2573897C2 (xx)
SI (1)	SI2342233T1 (xx)
TW (1)	TWI469792B (xx)
UA (1)	UA102867C2 (xx)
WO (1)	WO2010037831A1 (xx)
ZA (1)	ZA201102969B (xx)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2246364A1 (en) *	2009-04-29	2010-11-03	Pierre Fabre Médicament	Anti CXCR4 antibodies for the treatment of HIV
EP2371863A1 (en) *	2010-03-30	2011-10-05	Pierre Fabre Médicament	Humanized anti CXCR4 antibodies for the treatment of cancer
JP2014504147A (ja) *	2010-10-27	2014-02-20	ピエール、ファーブル、メディカマン	Ｈｉｖの治療用抗体
US20140120555A1 (en) *	2011-06-20	2014-05-01	Pierre Fabre Medicament	Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
ES2758884T3 (es)	2011-06-24	2020-05-06	Stephen D Gillies	Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas
AR087363A1 (es) *	2011-07-29	2014-03-19	Pf Medicament	Uso del anticuerpo i-3859 para la deteccion y diagnostico de los canceres
AR087364A1 (es)	2011-07-29	2014-03-19	Pf Medicament	Anticuerpo anti-cxcr4 y su uso para la deteccion y dianostico de canceres
NL2010658C2 (en) *	2013-04-18	2014-10-21	Bosch Gmbh Robert	Thermostat for a hvac.
TWI623551B (zh) *	2013-08-02	2018-05-11	輝瑞大藥廠	抗ｃｘｃｒ４抗體及抗體－藥物結合物
SG11201602060XA (en)	2013-09-23	2016-04-28	Wolf Wilson Mfg Corp	Improved methods of genetically modifying animal cells
AR104413A1 (es) *	2015-04-27	2017-07-19	Pf Medicament	Anticuerpo de igf-1r y su utilización para diagnosticar cáncer
MX2017015811A (es)	2015-06-12	2018-04-10	Squibb Bristol Myers Co	Tratamiento de cancer por bloqueo combinado de las trayectorias de señalizacion de muerte programada 1 (pd)-1 y receptor 4 de quimiocina c-x-c(cxcr4).
WO2017079833A1 (en)	2015-11-09	2017-05-18	The University Of British Columbia	Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto
US10759837B2 (en)	2015-11-09	2020-09-01	The University Of British Columbia	Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
US10973852B2 (en)	2016-01-25	2021-04-13	Nantcell, Inc.	NK cells with altered CXCL12/CXCR4 signaling
WO2017203799A1 (ja) *	2016-05-25	2017-11-30	株式会社東芝	エネルギー管理装置、管理システム、消費電力監視方法及びプログラム
IL263834B2 (en)	2016-06-20	2024-01-01	Kymab Ltd	Antibodies against PD-L1
US20180125920A1 (en)	2016-11-09	2018-05-10	The University Of British Columbia	Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
RU2748233C2 (ru) *	2017-01-31	2021-05-21	Мсм Протеин Текнолоджиз Инк.	Антитела против cxcr4
CN112513079A (zh)	2018-03-13	2021-03-16	拉巴斯大学医院生物医学研究基金会	用于癌症免疫疗法的联合激活和扩增的自然杀伤细胞的抗cxcr4抗体
CN110804100A (zh) *	2019-11-01	2020-02-18	中国人民解放军陆军特色医学中心	融合多肽及其在增强干细胞归巢能力和抗凋亡能力中的应用和药物组合物
TW202241935A (zh)	2020-12-18	2022-11-01	美商世紀治療股份有限公司	具有可調適受體專一性之嵌合抗原受體系統
CN112661845B (zh) *	2020-12-25	2022-06-21	暨南大学	与cxcr4结合的亲和力成熟结合蛋白及其应用
CN112521500B (zh) *	2020-12-25	2022-06-24	暨南大学	与cxcr4结合的亲和力成熟结合蛋白及应用
CN117003876A (zh) *	2023-08-31	2023-11-07	恺佧生物科技(上海)有限公司	一种Anti-CXCR4膜蛋白抗体及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4424200A (en)	1979-05-14	1984-01-03	Nuc Med Inc.	Method for radiolabeling proteins with technetium-99m
US4479930A (en)	1982-07-26	1984-10-30	Trustees Of The University Of Massachusetts	Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4831175A (en)	1986-09-05	1989-05-16	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
GB8924581D0 (en)	1989-11-01	1989-12-20	Pa Consulting Services	Bleaching of hair
GB9014932D0 (en)	1990-07-05	1990-08-22	Celltech Ltd	Recombinant dna product and method
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
JPH05244982A (ja)	1991-12-06	1993-09-24	Sumitomo Chem Co Ltd	擬人化ｂ−ｂ１０
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US6949243B1 (en) *	1999-11-24	2005-09-27	Schering Corporation	Methods of inhibiting metastasis
US20050002939A1 (en)	2002-12-23	2005-01-06	Albert Zlotnik	Tumor killing/tumor regression using CXCR4 antagonists
US9029097B2 (en) *	2005-02-16	2015-05-12	Universite De Montreal	Biosensors for monitoring receptor-mediated G-protein activation
CA2597717C (en) *	2005-02-18	2014-10-21	Dana-Farber Cancer Institute	Antibodies against cxcr4 and methods of use thereof
AU2009246683A1 (en) *	2008-05-14	2009-11-19	Eli Lilly And Company	Anti-CXCR4 antibodies

2008
- 2008-10-01 EP EP08305631A patent/EP2172485A1/en not_active Withdrawn
2009
- 2009-09-30 TW TW98133164A patent/TWI469792B/zh not_active IP Right Cessation
- 2009-10-01 DK DK09744645.4T patent/DK2342233T3/da active
- 2009-10-01 CN CN200980144491.4A patent/CN102209730B/zh not_active Expired - Fee Related
- 2009-10-01 RS RSP20140515 patent/RS53578B1/en unknown
- 2009-10-01 WO PCT/EP2009/062787 patent/WO2010037831A1/en active Application Filing
- 2009-10-01 KR KR1020117009556A patent/KR101671039B1/ko active IP Right Grant
- 2009-10-01 AU AU2009299787A patent/AU2009299787B2/en not_active Ceased
- 2009-10-01 JP JP2011529559A patent/JP5723279B2/ja not_active Expired - Fee Related
- 2009-10-01 PL PL09744645T patent/PL2342233T3/pl unknown
- 2009-10-01 UA UAA201105412A patent/UA102867C2/uk unknown
- 2009-10-01 EP EP09744645.4A patent/EP2342233B1/en active Active
- 2009-10-01 MX MX2011003509A patent/MX2011003509A/es active IP Right Grant
- 2009-10-01 NZ NZ592363A patent/NZ592363A/xx not_active IP Right Cessation
- 2009-10-01 AR ARP090103802A patent/AR073748A1/es unknown
- 2009-10-01 PT PT97446454T patent/PT2342233E/pt unknown
- 2009-10-01 ES ES09744645.4T patent/ES2503732T3/es active Active
- 2009-10-01 BR BRPI0920531-4A patent/BRPI0920531A2/pt not_active IP Right Cessation
- 2009-10-01 MA MA33784A patent/MA32928B1/fr unknown
- 2009-10-01 RU RU2011115559/10A patent/RU2573897C2/ru not_active IP Right Cessation
- 2009-10-01 SI SI200931016T patent/SI2342233T1/sl unknown
- 2009-10-01 GE GEAP200912211A patent/GEP20146084B/en unknown
- 2009-10-01 CA CA2738782A patent/CA2738782C/en not_active Expired - Fee Related
2010
- 2010-03-30 US US12/749,891 patent/US8557964B2/en not_active Expired - Fee Related
2011
- 2011-03-31 IL IL212066A patent/IL212066A/en not_active IP Right Cessation
- 2011-04-01 CL CL2011000730A patent/CL2011000730A1/es unknown
- 2011-04-20 ZA ZA2011/02969A patent/ZA201102969B/en unknown
- 2011-06-23 US US13/167,329 patent/US20110287451A1/en not_active Abandoned
- 2011-06-23 US US13/167,321 patent/US20110294156A1/en not_active Abandoned
2012
- 2012-04-05 HK HK12103380.8A patent/HK1163119A1/xx not_active IP Right Cessation
2013
- 2013-09-13 US US14/025,875 patent/US9388248B2/en not_active Expired - Fee Related
2014
- 2014-09-22 HR HRP20140899AT patent/HRP20140899T1/hr unknown
- 2014-09-24 CY CY20141100778T patent/CY1115572T1/el unknown

Also Published As

Publication number	Publication date
IL212066A (en)	2015-05-31
US20110294156A1 (en)	2011-12-01
AU2009299787B2 (en)	2015-06-18
AU2009299787A2 (en)	2011-06-02
ES2503732T3 (es)	2014-10-07
CA2738782A1 (en)	2010-04-08
NZ592363A (en)	2012-08-31
US8557964B2 (en)	2013-10-15
UA102867C2 (uk)	2013-08-27
CN102209730B (zh)	2014-11-05
ZA201102969B (en)	2011-12-28
IL212066A0 (en)	2011-06-30
CN102209730A (zh)	2011-10-05
EP2172485A1 (en)	2010-04-07
BRPI0920531A2 (pt)	2021-02-23
MX2011003509A (es)	2011-05-02
HRP20140899T1 (hr)	2014-11-07
PL2342233T3 (pl)	2014-11-28
PT2342233E (pt)	2014-10-03
KR20110081229A (ko)	2011-07-13
DK2342233T3 (da)	2014-09-29
US20110287451A1 (en)	2011-11-24
KR101671039B1 (ko)	2016-11-01
US9388248B2 (en)	2016-07-12
JP2012504401A (ja)	2012-02-23
EP2342233B1 (en)	2014-06-25
TW201018483A (en)	2010-05-16
RS53578B1 (en)	2015-02-27
US20140050661A1 (en)	2014-02-20
RU2011115559A (ru)	2012-11-10
GEP20146084B (en)	2014-05-13
WO2010037831A1 (en)	2010-04-08
EP2342233A1 (en)	2011-07-13
AU2009299787A1 (en)	2010-04-08
TWI469792B (zh)	2015-01-21
RU2573897C2 (ru)	2016-01-27
SI2342233T1 (sl)	2014-10-30
MA32928B1 (fr)	2012-01-02
AR073748A1 (es)	2010-12-01
US20110020218A1 (en)	2011-01-27
CL2011000730A1 (es)	2012-02-03
JP5723279B2 (ja)	2015-05-27
CA2738782C (en)	2017-11-28
CY1115572T1 (el)	2017-01-04

Legal Events

Date	Code	Title	Description
2020-05-15	PC	Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)	Effective date: 20191001

Publication	Publication Date	Title
HK1163119A1 (en)	2012-09-07	Anti cxcr4 antibodies and their use for the treatment of cancer cxcr4
IL247183B (en)	2020-06-30	Secretory-apoptosis factors for the treatment of cancer and immune and autoimmune diseases
IL213070A0 (en)	2011-07-31	Methods for the treatment of infections and tumors
EP2277049A4 (en)	2012-05-30	AUTOANTIBODIES IN THE DETECTION AND TREATMENT OF CANCER
PL2532364T3 (pl)	2016-11-30	Kompozycja farmaceutyczna zawierająca przeciwciała anty CAPRIN-1 do leczenia i/lub zapobiegania nowotworowi
EP2216344A4 (en)	2010-12-29	DIAGNOSIS AND TREATMENT OF CANCER WITH AN ANTI-GPR49 ANTIBODY
HK1159498A1 (en)	2012-08-03	Methods and compositions for the treatment of cancer
EP2652506A4 (en)	2015-03-25	USE OF ANTIBODIES AGAINST CXCL16 AND CXCR6 FOR TREATMENT OR FOR THE DETECTION OF CANCER
EP2652508A4 (en)	2015-07-15	USE OF ANTI-CXCL13 ANTI-CXCR5 ANTIBODIES FOR THE TREATMENT OR DETECTION OF CANCER
EP2340027A4 (en)	2012-04-04	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
HK1178910A1 (en)	2013-09-19	Humanized anti cxcr4 antibodies for the treatment of cancer cxcr4
GB0807018D0 (en)	2008-05-21	Antibodies and treatment
EP2391363A4 (en)	2012-09-19	COMPOSITIONS AND METHOD FOR CANCER TREATMENT
EP2144887A4 (en)	2012-10-03	PHARMACEUTICAL FORMS AND METHOD FOR THE TREATMENT OF CANCER
EP2150270A4 (en)	2011-09-28	METHODS AND COMPOSITIONS FOR TREATING CANCER
EP2377891A4 (en)	2012-08-29	DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-LGR7 ANTIBODY
EP2420515A4 (en)	2013-08-28	DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-TMPRSS11E ANTIBODY
EP2331130A4 (en)	2012-11-07	IGE ANTIBODIES FOR THE TREATMENT OF CANCER
HUE031337T2 (hu)	2017-07-28	Opioidok rezisztens rákos betegek kezelésében történõ alkalmazásra
EP2361317A4 (en)	2014-01-01	USE OF EIF3M FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP2411031A4 (en)	2012-08-01	Methods and compositions for the treatment of cancer
EP2123676A4 (en)	2011-01-05	DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-PRG-3 ANTIBODIES
HK1209754A1 (en)	2016-04-08	Compounds and methods for the treatment of cancer
GB0700281D0 (en)	2007-02-14	Methods and Means for the Treatment of Cancer
IL211752A0 (en)	2011-06-30	Antibody combinations and use of same for treating cancer